NCT01299727 - Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2011

Primary Completion Date

April 12, 2019

Study Completion Date

April 12, 2019

Conditions

Sanfilippo Syndrome

Interventions

BIOLOGICAL

rhHNS-10 mg

Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years

BIOLOGICAL

rhHNS-45 mg

Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years

BIOLOGICAL

rhHNS-90 mg

Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years

Trial Locations (2)

Emma Children's Hospital, Academic Medical Center, Amsterdam

St. Mary's Hospital, Manchester